PV-AIM: using machine learning to predict resistance to hydroxyurea therapy in patients with PV

Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares insights into the the ‘Polycythemia Vera: A Machine Learning Study’ (PV-AIM) study which used electronic medical records to predict study which used electronic medical records to predict resistance to treatment with hydroxyurea in patients with polycythemia vera (PV). Prof. Verstovsek explains that two parameters - hemoglobin and red-cell distribution width (RDW) – can be used to effectively predict the outcomes of patients with PV treated with hydroxyurea. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Please note that if you are under 18, you won't be able to access this site.

Up next

PV-AIM: using machine learning to predict resistance to hydroxyurea therapy in patients with PV

Up next

Language